Stavanger Universitetssjukehus
Stavanger, Norway
NCT Number: NCT05829382
A randomized, double-blind, placebo controlled, cross-over trial to investigate the effect of the Investigational Product "DailyColors™" (DC) on age-related pathways in adults.
The aim of this study is to measure the effects of acute treatment with DC on key pathways relevant to healthy ageing using blood biomarkers.
Based on power calculations a sample size of 20, is sufficient to detect an effect size of 0.46 at a power > 90%. To account for dropout the investigators will include 26 subjects in total.
Looking for future studies?
Notify Me55 year–80 year
All sexes
Interventional
Not applicable
Stavanger, Norway
Aims:
The aim of this study is to measure the effects of acute treatment with DC on key pathways relevant to healthy ageing using blood biomarkers.
Hypotheses:
There will be preliminary evidence that the IP has positive clinical effects on biologically relevant pathways related to healthy aging of brain and muscle including blood markers of inflammation, oxidative stress markers, and trophic factors.
Design:
A randomized, double-blind, placebo controlled, cross-over trial to investigate the effect of the Investigational Product (DailyColors™) on age-related pathways in adults. Participants will receive DailyColors™ or placebo for a week, then one week wash-out, and then placebo/Dailycolors™ for a week, in random order. In addition, participants will be invited to participate in an open-label extension study for 3 months.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Capsule containing active ingredient administred daily by the participant during the trial period
Capsule containing placebo administered daily by the participant during the trial period
Time frame: 3 weeks
Change from baseline in the blood levels of CD38 at 1hour, 2 hours, 24 hours and week 1 and week 3. Blood CD38 is measured using commercially available immunoassays.
Time frame: 3 weeks
Change from baseline in the blood levels of NAD+ at 1hour, 2 hours, 24 hours and week 1 and 3. Blood NAD+ is measured using commercially available assay kits.
Time frame: 3 weeks
Change from baseline in the blood levels of inflammatory biomarkers, such as IL-6, TNF-α and IL-10, and IL-8 at week 1 and 3. All blood biomarkers are measured using commercially available immunoassays. All biomarkers have the same unit of measure, namely pg/mL.
Time frame: 3 weeks
Change from baseline in the blood-based total antioxidant capacity at week 1 and 3, which are measured using commercially available assays.
Time frame: 3 weeks
Change from baseline in the blood levels of 4-HNE at week 1 and week 3, which are measured using commercially available assays.
Time frame: 3 weeks
Change from baseline in the blood levels of protein carbonyl at week 1 and week 3, which are measured using commercially available assays.
Helse Stavanger HF
Other Gov
A Randomized, Double-blind, Placebo Controlled, Cross-over Clinical Trial of Acute Safety and Biological Effects of a Polyphenol Supplement
Acronym: MIDI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04149457
Healthy Aging
Montreal, Quebec, Canada
View Trial DetailsNCT04522791
Cognition Disorders, Cognitive Dysfunction
Rochester, New York, United States
View Trial DetailsNCT04848038
Healthy Aging
Fairway, Kansas, United States
View Trial DetailsNCT07623122
Cognition Disorders, Cognitive Decline
Pamplona, Navarre, Spain
View Trial Details